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The heart is a major consumer of energy and is able to utilise a wide range of substrates including lipids. Nonesterified fatty
acids (NEFA) were thought to be a favoured carbon source, but their quantitative contribution is limited because of their relative
histotoxicity. Circulating triacylglycerols (TAGs) in the form of chylomicrons (CMs) and very-low-density lipoprotein (VLDL) are
an alternative source of fatty acids and are now believed to be important in cardiac metabolism. However, few studies on cardiac
utilisation of VLDL have been performed and the role of VLDL in cardiac energy metabolism remains unclear. Hearts utilise
VLDL to generate ATP, but the oxidation rate of VLDL-TAG is relatively low under physiological conditions; however, in certain
pathological states switching of energy substrates occurs and VLDL may become a major energy source for hearts. We review
research regarding myocardial utilisation of VLDL and suggest possible roles of VLDL in cardiac energy metabolism: metabolic
regulator and extracardiac energy storage for hearts.
1. Introduction
Very-low-density lipoprotein (VLDL) and chylomicrons
(CM) comprise the triacylglycerol-(TAG-) rich lipoproteins
in the circulation. The assembly and secretion of VLDL
particles takes place in parenchymal liver cells. The basic
structure of VLDL is such that the hydrophobic triacyl-
glycerol molecules, together with cholesterol ester, form
the particle core and are coated by a relatively hydrophilic
monolayer consisting of phospholipids, free-cholesterol, and
apolipoproteins [1–3]. Apolipoprotein (apo) B100 is a 4536
amino acid glycoprotein, synthesised in the liver and the
major structural protein of VLDL. Interestingly, each VLDL
particle has just one copy of apo-B100, which means
the concentration of apo-B100 represents the number of
particles, and this molecule constitutes the basic scaﬀolding,
upon which other compositional components are attached
during the assembly process of the lipoprotein.
The TAG core of the VLDL particle is synthesised by liver
cells using diﬀerent endogenous fatty acid sources. These
include fatty acids derived from hydrolysis of adipose tissue
TAG stores (lipolysis), fatty acids derived from peripheral
hydrolysis of plasma lipoprotein (VLDL and chylomicron)
TAG cleared by the liver, and newly synthesised fatty acids
via hepatic de novo lipogenesis [4]. Therefore, VLDL has been
regarded as a transport vehicle responsible for redistribution
of endogenous lipids from liver to peripheral tissues.
But what is the purpose of this redistribution? It appears
that the major function of hepatic VLDL secretion is to
buﬀer plasma “free” fatty acid levels through their conversion
to core VLDL-TAG [4]. In part, the consequence of this
conversion is that energy contained within fatty acid is
stored and transported in an alternative (nontoxic) form,
the esterified fatty acid-VLDL TAG core. This is of particular
importance for the heart since lipids are the major cardiac
energy substrates.
Cardiac function is critically dependent on substrate
utilisation, and changes in myocardial substrate selection
can have a major impact, both positively and negatively, on
myocardial contraction [5]. The heart is capable of utilising
a wide variety of substrates including carbohydrates, lipids,
amino acids, and ketone bodies for its energy requirements,
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but this utilisation is condition-dependent according to
substrate availability and work load. Although amino acids
and ketone bodies are energetic substrates for heart, the
heart’s energy requirement is mainly furnished by provision
of circulating carbohydrates and lipids through the coronary
vasculature under normal aerobic conditions. The heart
can also use its internal stores of energy, that is, glycogen
and TAG, under certain circumstances, but this supply is
quantitatively limited. However, current evidence suggests
that most (∼70%) of energy for heart is derived from
the oxidation of fatty acids under physiological work load
conditions [1, 6–8].
This conclusion has raised another important question.
Because fatty acids are derived from both plasma albumin-
bound nonesterified fatty acids (NEFAs) and plasma TAG-
rich lipoproteins (TGRLPs), that is, VLDL and chylomicrons,
what therefore is the relative contribution of each lipid source
to the cardiac energy requirement?
So far, many studies have been conducted to investigate
the utilisation of NEFA (and to a lesser extent, chylomi-
crons) by heart. However, unlike these two FA sources,
the true physiological role of VLDL within cardiac energy
metabolism still remains uncertain: very few studies have
been reported, and findings from these studies are somewhat
discrepant. In this paper, we review these reports on the
utilisation of VLDL by the myocardium, aiming to outline
the possible role of VLDL in heart metabolism.
2. Can the Heart Function with VLDL?
Since the pioneering studies of Bing et al. [9], it has been
fully appreciated that fatty acids are important substrates for
myocardial energy requirements. However, it has not been
clear what is the contribution of non-esterified fatty acid and
esterified fatty acid to myocardial energy production. Even
four decades later, it was still widely presumed that NEFA is
the primary source of energy for the heart [8, 10], despite
the fact that the molar concentration of fatty acid in TAG-
rich lipoproteins may be up to an order of magnitude greater
than that of albumin-bound NEFA [11].
However, in 1960, Ballard and colleagues suggested that it
was actually esterified fatty acids which accounted formost of
the total fatty acids extracted by the myocardium [12]. They
found that during fasting more than 50% of fatty acids taken
up by human hearts were derived from esterified fatty acids;
in fasting dog, this figure was 77%. Importantly, this was the
first experiment to show that the heart can utilise VLDL as a
fuel because during fasting most of the esterified fatty acids
are transported within the VLDL-TAG core.
Unfortunately, since then, although there have been some
investigations on lipoprotein utilisation by heart [13, 14],
compared to the multiple studies on cardiac non-esterified
fatty acid metabolism, relatively few studies have examined
this aspect of myocardial substrate selection. This is partly
due to the diﬃculty in obtaining suﬃcient quantities of
VLDL to test in an isolated heart system. In 2000, Bennett
et al. [15] reported an extended liver perfusion technique to
prepare species-specific radiolabelled VLDL.
Following this technique, Hauton et al. investigated
myocardial lipid substrate preference by comparing utili-
sation of NEFA, VLDL-TAG, and CM-TAG in isolated rat
“working” hearts [10]. Cardiac mechanical function was
maintained regardless of lipid substrate used. In other words,
like NEFA and CM, VLDL is capable of supporting the
heart energetically. However, some diﬀerences did exist: for
example, the utilisation of VLDL-TAG by hearts was less than
that of NEFA and CM-TAG.
This is of particular interest. Mechanical performance
of hearts perfused with VLDL as the sole source of lipid
was comparable to those perfused with CM and/or NEFA,
suggesting either that glucose oxidation is increased in
VLDL perfused hearts, which has been shown not to be
the case by our own work [16], or that “eﬃciency” of
VLDL-TAG utilisation is greater than that of CM-TAG or
NEFA (same work output for less substrate oxidised). If
this is true, it could reasonably explain why under some
energy stress conditions, such as diabetes [16] and sepsis
[17], the utilisation and oxidation of VLDL are significantly
increased. Indeed, in our previous work, there was evidence
supporting this hypothesis: when the uptake pathway for
VLDL was blocked, cardiac mechanical performance was
severely aﬀected [18], suggesting an important physiological
role for this relatively small amount of lipid substrate
assimilated by the heart.
These findings of significantmyocardial VLDL utilisation
were subsequently confirmed and extended [18]. Using
radio-labelled VLDL particles from rat liver perfusions
in isolated rat “working” heart preparations, we found
that under normal physiological conditions, the myocardial
uptake and utilisation of VLDL was less than that of CM, but
mechanical function of the heart was comparable. Another
significant diﬀerence was that only about half the VLDL-
TAG assimilated by the heart was oxidized, whereas the pro-
portion of CM-TAG oxidised reached 80%, indicating that
the portion of TAG-rich lipoprotein-derived lipid channelled
towards nonoxidative pathways (e.g., incorporation into
tissue lipids) was protected. Considering that the heart can
utilise carbohydrates, NEFA, CM, VLDL, amino acids, and
so on as its fuel substrates under physiological conditions,
VLDL probably functions diﬀerently to NEFA and CM
in myocardial energy metabolism. Significantly, Hauton et
al. [10] found that CM-TAG utilisation but not VLDL-
TAG utilisation was suppressed in the presence of NEFA.
However, TAG did not alter NEFA utilisation, suggesting
that NEFA provides a significant contribution to the energy
requirements of the working heart, whilst VLDL-derived
lipid is preferentially required for nonoxidative metabolism.
However, there are studies challenging this conclusion.
Elegant experiments by Goldberg’s group utilising labelled
TAG emulsions [11] suggested that fatty acid derived from
the hydrolysis of TAG-rich lipoproteins may be the primary
source of fatty acid utilised by the heart, particularly in the
fed state. By using a new animal model with overexpression
of anchored lipoprotein lipase (LPL) on the surface of
cardiomyocytes (hLpLGPI mice), Pillutla et al. [19] also
found that VLDL isolated from fasting blood inhibited
the uptake and oxidation of palmitate in the perfusate of
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both hLpLGPI and wild-type hearts, suggesting that hearts
can use TAG-derived fatty acids as an alternative fuel, and
in some situations, as the primary source of fatty acid.
Direct measurements of CM-TAG utilisation by mouse
heart supports the importance of TAG-rich lipoproteins
in cardiac energy provision [20, 21]. Furthermore, tissue-
specific inhibition of cardiac TAG uptake by selective cardiac
LPL knockout reveals both that the heart is a quantitatively
important “sink” for plasma TAG [22] and that long-term
cardiac function depends on adequate TAG provision (see
below) [23].
Therefore, there is now little doubt that VLDL plays an
important role in myocardial energetics and function, at
least by acting as a metabolic substrate. But the diﬀerence
in this aspect between VLDL and other lipid sources, such
as CM and NEFA, could be of more important significance.
Because its utilisation by the heart is relatively low but its
eﬃciency is high, it is possible that VLDL serves as an
alternative source of fatty acids for hearts under energy-
stress conditions; however, under normal conditions, CM
and NEFA are the major fatty acid (oxidative) sources for the
heart whilst VLDLmight play a regulatory role in myocardial
lipid metabolism.
3. Is Lipoprotein Lipase or
VLDL Receptor Responsible for
the Uptake of VLDL by the Heart?
In 1943, Hahn reported that following heparin injection,
the dog had decreased postprandial lipaemia [24], indicating
that heparin caused the presence of a so-called lipid “clearing
factor” in the circulation. This was the first work suggesting
the role of lipoprotein lipase (LPL, E.C.3.1.1.34) in lipopro-
tein metabolism. It is now believed that LPL is the principal
enzyme responsible for hydrolysis of TAG circulating within
lipoproteins, making the fatty acids released available for use
by subjacent tissues.
There is strong evidence that heart expresses the LPL gene
abundantly [25, 26]. Indeed, cardiac LPL activity alone (in
the absence of LPL expression in other tissues) can normalise
plasma TAG concentration in cardiac rescue LPL knockout
mice [27]. LPL is synthesised by parenchymal heart cells,
but requires subsequent transfer to the luminal surface of
the endothelial cell, where it is bound to heparan sulphate
proteoglycan (HSPG), in order to be physiologically active
(functional). Hydrolysis of TAG by endothelium-bound LPL
is widely regarded as the initial step for the “bulk” uptake
of lipoprotein-TAG by peripheral tissues, including the heart
[11, 22, 28–31]. Indeed, we found a significant decrease in
the uptake and utilisation of VLDL-TAG (and CM-TAG) by
the heart after LPL activity was inhibited [18], supporting
a major role for LPL in mediating myocardial VLDL lipid
assimilation, a conclusion supported by Cheng and Hauton
who noted a correlation between cardiac LPL activity and
TAG uptake during metabolic stress [32]. Interestingly,
however, cardiac mechanical performance was not aﬀected
when VLDL utilisation was decreased [18], suggesting that
there could be another mechanism for the heart to take
up VLDL, and this small pool of VLDL is eﬀective in
maintaining the heart in good working condition even when
LPL-mediated hydrolysis is blocked.
It should be noted that LPL-mediated hydrolysis of
lipoproteins can occur in the plasma following LPL release
from the endothelial cell surface by heparin; hence, Hahn
found a rapid clearance of blood lipid after injection of
heparin [24]. Moreover, some LPL probably dissociate from
the endothelial cell in association with the lipoprotein
particle during lipolysis and continues to lipolyse TAG-rich
lipoproteins in the bloodstream. But it is still not clear how
much lipolysis occurs on the cell surface compared to the
plasma [30], and what the relative contribution of these two
sources of lipolysis is to cardiac energy provision.
Although LPL is also present on the surface of cardiomy-
ocytes, it is generally believed that the luminal surface of the
endothelial cell is the site where hydrolysis of the lipoprotein-
TAG core take place. However, by using a transgenic mouse
model with an LPL transgene construct expressed and
anchored on the cardiomyocyte surface, Yagyu et al. [33]
found that this pool of LPL was responsible for the increased
uptake of TAG by the heart. Furthermore, a new model of
cardiomyopathy was created due to the excessive myocardial
uptake of TAG via LPL action, suggesting that cardiomyocyte
cell surface LPL is physiologically functional in terms of
mediation of cardiac TAG uptake.
As reactant and product of the lipolytic process, respec-
tively, TAG and free fatty acid have diﬀerent eﬀects on
LPL activity. Circulating TAG increased LPL activity at the
coronary lumen but decreased it on the cardiomyocyte cell
surface, suggesting that TAG facilitates LPL translocation
from cardiomyocyte to the myocardial endothelial lining
[34], and we found that VLDL was capable of modulating
LPL translocation in isolated hearts [10, 18]. However,
Anderson et al. [35] found that free fatty acids selectively
decreased heparin-releasable LPL activity in cultured car-
diomyocytes, possibly through end-product inhibition of
lipolytic processes, and despite an increase in immunode-
tectable LPL on the cardiomyocyte cell surface.
All these studies suggest that LPL is responsible for the
uptake of VLDL-TAG by the heart. However, other factors
may be important in VLDL assimilation.
In 1967, Enser et al. [14] used 14C labelled chyle lipids
to perfuse isolated rat hearts. They found that at least part
of the 14CO2 production could have been derived from
the oxidation of 14C labelled free fatty acid produced in
the perfusion medium via the function of the so-called
“clearing-factor lipase”. They also found that the whole lipid
particle was being taken up and oxidised by the heart. These
results suggested that TAG-rich lipoprotein could both be
hydrolysed to produce free fatty acid outside the heart and
could also be taken up by the heart as a whole particle.
To our knowledge, this was the first work to indicate that
besides the LPL-mediated hydrolysis there is an alternative
mechanism for hearts to assimilate TAG-rich lipoproteins.
It is now believed that this pathway is receptor-mediated
endocytosis.
At least two kinds of lipoprotein receptor may be impor-
tant in the myocardium in this respect: the VLDL receptor
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[36–39] and the apo-B48 receptor [40], both of which have
been found in abundance in those tissues active in fatty acid
utilisation, including heart, suggesting a potential role in
delivery of fatty acid to these tissues for metabolic purposes.
The VLDL receptor (VLDL-R) is a 118-kDa protein
and a member of the expanding mammalian low density
lipoprotein receptor (LDL-R) gene family with ligand speci-
ficity: it binds apo-E but not apo-B. Notwithstanding some
species diﬀerences in tissue distribution of VLDL-R [41],
it is reasonable to believe that this receptor is responsible
for the delivery of VLDL particles into the heart. Indeed,
since VLDL-R cDNA was cloned in 1992 [42], many studies
have been performed to identify the function(s) of this
receptor and findings are comparable, which suggests a rela-
tionship between myocardial VLDL-R expression and VLDL
uptake.
For example, VLDL-R protein expression in heart was
found to increase progressively with fasting [43], suggesting
its potential role of delivering VLDL-TAG to themyocardium
since VLDL production is increased in fasting. In addition,
in hypertrophic hearts, VLDL-R mRNA decreased [44];
the decreased VLDL-R expression could be linked to the
energy substrate switch from lipid to glucose known to
occur in myocardial hypertrophy [45, 46]. Kamataki et al.
also found that in the Balb/c fasting mice, VLDL-R as well
as other molecules involved in cardiac lipid metabolism,
including LPL, increased [47]. This is probably a mechanism
for heart to adapt to diﬀering energetic situations. More
recently, Zenimaru et al. [48] found that glucose deprivation
from the culture medium significantly induced AMPK
activation, followed by increased VLDL-R expression and
hence increased uptake of VLDL in rat L6 myoblasts. This
is interesting because it suggests that the heart tends to
utilise the more “eﬃcient” VLDL via regulation of VLDL-R
expression to deal with the substrate switch from glucose to
lipid utilisation which is known to occur in conditions such
as fasting, sepsis, and diabetes [45].
However, we used suramin to block lipoprotein receptors
on the cardiomyocyte surface [18] and demonstrated some
interesting findings. Firstly, VLDL-TAG fatty acid uptake
was not aﬀected during receptor blockade but VLDL par-
ticle uptake was inhibited (confirmed by decreased VLDL-
cholesterol uptake by the heart); secondly, the oxidation rate
of VLDL-TAG significantly decreased and the proportion
of TAG oxidised also decreased; thirdly, cardiac mechanical
function was significantly impaired following lipoprotein
receptor blockade [18]. Given that myocardial VLDL-TAG
uptake and utilisation, but not cardiac mechanical function,
decreased when LPL was inhibited, these results suggest
that, although quantitatively less important than LPL-
mediated hydrolysis, VLDL receptor-mediated uptake is
a functionally critical mechanism for the heart to eﬀec-
tively utilise VLDL. Furthermore, receptor-mediated TAG
uptake is preferentially directed towards oxidation rather
than esterification, suggesting a correlation between lipid
uptake mechanisms and metabolic “channeling” within the
cardiomyocyte [18].
Unlike the VLDL receptor, the apo-B48 receptor is an
apo-E- and LPL-independent membrane protein originally
found to be responsible for the uptake of TGRLP by retic-
uloendothelial system (and hence also termed the TGRLP
receptor), and believed to deliver lipid and lipid-soluble
vitamins to monocyte-macrophages for nutritional purposes
under physiological conditions [49]. However, little is known
about its role in cardiac lipid metabolism. Clues are that
peroxisome proliferator-activated receptor (PPAR)-α and
PPARγ activators significantly suppress the expression of
apo-B48 receptor mRNA in human monocyte-macrophages;
moreover, these activators also inhibit the expression of the
apo-B48 receptor protein and; hence, the receptor-mediated
lipid accumulation of TGRLP by monocytes in vitro [50, 51].
Because the heart expresses PPARα, PPARγ, and apo-B48
receptor (albeit the last at relatively low level), it is possible
that the apo-B48 receptor could also be involved in cardiac
lipid metabolism.
Clearly, both LPL and lipoprotein receptors (including
the VLDL receptor) are responsible for the uptake of
VLDL-TAG (as well as chylomicrons remnants [52]) by the
heart—but several lines of evidence suggest that interactions
between the two mechanisms exist. There are at least three
putative mechanisms of interplay between LPL and VLDL-R
[37, 38]: (1) as a ligand, LPL can directly bind to the receptor;
(2) acting as a molecular “bridge”, LPL facilitates the binding
of VLDL particles to heparan sulphate proteoglycans prior
to interaction with the receptor [38]; (3) LPL converts
VLDL particles to smaller remnants (intermediate density
lipoprotein (IDL)), which can subsequently be endocytosed
by the receptor (see [53]).
However, interactions between VLDL-R and LPL could
work in a reverse fashion: the VLDL receptor acts as an
“anchor” to facilitate hydrolysis of TAG-rich lipoproteins
by LPL [54]. Indeed, VLDL-R-deficient mice have reduced
LPL activity because the VLDL receptor is involved in the
translocation of LPL from cardiomyocytes to the endothelial
surface [55], causing hypertriglyceridaemia associated with
reduced catabolism of VLDL-TAG by LPL. Further strong
support for this mechanism is that Receptor-Associated
Protein (RAP), a 39-kDa protein that inhibits both the LDL
receptor-related protein and the VLDL receptor, also inhibits
LPL activity in mice expressing VLDL-R, but RAP is less
eﬀective in VLDL-R knockout animals [55]. The eﬀect of
RAP on LPL is presumably therefore at least partly via its
inhibition of VLDL-R, which again supports the concept of
the regulation of LPL by VLDL-R.
Although the two mechanisms are responsible for the
uptake of VLDL by the heart, under physiological conditions,
myocardial utilisation of VLDL is relatively low [10, 18].
This suggests that compared to other lipid substrates such
as NEFA and CM, VLDL does not act as a major energy
source for hearts in this situation. Therefore, what is the
true physiological role of VLDL? Because it is the ligand
for both LPL and VLDL-R, VLDL itself could be a “bridge”
connecting the two proteins and act as an important
regulator in cardiac energy metabolism; also, because VLDL-
TAG core is a more “eﬃcient” lipid substrate for the heart
[10, 16, 18] it could be an alternative or “external” energy
storage for hearts to utilise in order to adapt to various
energy-stress conditions, such as diabetes.
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4. How Does VLDL Utilisation by the
Heart Change in Diabetes?
In diabetes, downregulated glucose transport and metab-
olism as the consequence of insulin deficiency (type 1) and
resistance (type 2), result in fatty acid oxidation becoming
the almost exclusive energy source for the heart [45, 56,
57]. Little is known about TAG metabolism in the diabetic
heart, but investigation of myocardial utilisation of VLDL
in diabetes could provide some clues about the role of
this particle in cardiac energy metabolism. To date, the
findings relating to cardiac TAG metabolism in diabetes are
extremely discrepant, making it diﬃcult to discern the true
role of VLDL, and this may be a reflection of widely varying
models of disease severity and length of exposure [58]. Both
decreased and increased VLDL utilisation by the heart have
been reported. Interestingly, however, the two apparently
incompatible findings can each explain two widely accepted
features of diabetes: hypertriglyceridaemia and diabetic
cardiomyopathy (a severe cardiovascular complication due
to “lipotoxicity” rather than other cardiac risk factors, such
as hypertension and coronary atherosclerosis).
Decreased cardiac LPL activity in diabetic rodent hearts
has been reported [59, 60]. In 1983, O’Looney et al. [60]
reported decreased VLDL metabolism by streptozotocin
(STZs) induced diabetic hearts, associated with decreased
heparin-releasable LPL activity, both eﬀects were completely
reversed by the administration of insulin. More recently,
cardiac VLDL-R protein levels, as well as postheparin LPL
activity, were found to decline significantly in STZ-induced
diabetes [61]. Yagyu et al. [55] also found that disruption
of VLDL-R resulted in hypertriglyceridaemia associated with
decreased LPL activity in mice. In addition, Kobayashi et
al. [59] observed decreased postheparin LPL activity in
db/db mice, a type 2 diabetic animal model. These results
could explain diabetic hypertriglyceridaemia; additionally,
in support of this mechanism, Chen et al. found that
hypertriglyceridaemia in STZ rats was not primarily due to
VLDL overproduction in liver but to a peripheral VLDL-
TAG removal defect [62]: since LPL and VLDL-R are both
down-regulated in diabetes, VLDL particles accumulate in
the plasma, resulting in hypertriglyceridaemia.
However, decreased LPL activity and VLDL-R deficiency
in diabetes cannot explain the increased fatty acid oxidation
observed in these hearts, which is another characteristic
feature of the diabetic state. In contrast to the findings
reported above, meticulous research conducted in Rodrigues’
group demonstrated increased cardiac heparin-releasable
LPL activity in STZ-diabetic [58] and SHR-diabetic rats
[63], which they hypothesised could increase fatty acid
supply to the heart. Subsequent studies from the same group
confirmed the hypothesis in this model: increased myocar-
dial VLDL metabolism associated with elevated heparin-
releasable LPL activity in STZ-induced moderately diabetic
rat hearts was reported [64]. The authors believed that the
rapid removal of VLDL-TAG by diabetic heart could be
one mechanism for the increased provision of fatty acid
for energy production, to compensate for the diminished
contribution of glucose as an energy source. Furthermore,
this mechanism could be responsible for the development of
diabetic cardiomyopathy due to excess delivery of potentially
toxic fatty acid to the heart (“lipotoxicity”). Intracellular
lipids accumulate and can, either by themselves or via
production of secondmessengers such as ceramides, provoke
cell death [25, 65].
Our studies support Rodrigues’s findings. We found that
cardiac heparin-releasable LPL activity increased in both
type 1 [16] and type 2 diabetic rats [66], and VLDL-
TAG oxidation increased significantly in diabetic hearts. In
addition, when hearts from both control and diabetic rats
were perfused with VLDL particles prepared from STZ-
treated animals, heparin-releasable LPL activity increased,
suggesting that diabetic VLDL particles may stimulate LPL
activity, and indicating a possible regulatory role for VLDL.
Consistent with this, we have also found significant intra-
cellular TAG accumulation, derived from exogenous VLDL,
in both types of diabetes regardless of unimpaired cardiac
function at an early stage of the disease [16, 66]. Further
evidence of a role for VLDL as a metabolic signal and cellular
regulator has recently been provided by the demonstration
that VLDL modulates myocardial SERCA-2 expression and
calcium handling, an eﬀect potentiated by hypoxia [67].
One explanation for the variable and condition-
dependent nature of VLDL action and metabolism may
be the complex nature (and potentially key importance)
of the composition of the VLDL particle itself. VLDL
particles are composed of proteins and lipids. The apoprotein
components maintain the structure of the particles but
also have regulatory and signalling functions [68]; lipid
constituents include TAG, phospholipids (PL), cholesterol,
cholesterol ester, and free fatty acids, with potentially com-
plex surface interactions with target routes. Furthermore,
dynamic alterations in the composition of VLDL particles
occur physiologically as well as pathologically, and this can
profoundly aﬀect their eﬃcacy as a target and substrate for
both LPL and VLDL-R. Upon its entry into the bloodstream,
VLDL acquires apo-C and apo-E by transfer from circulating
plasma high-density lipoproteins (HDL). Subsequently, the
TAG core of VLDL is hydrolysed by lipoprotein lipase (LPL),
resulting in free fatty acid release and formation of smaller
remnant particles, that is, intermediate-density lipoprotein
(IDL), and ultimately low-density lipoprotein (LDL) which
are enriched in cholesterol. The remnant particles are cleared
from the plasma by receptor-mediated endocytosis [69]. Any
compositional alteration is of great potential significance
regarding metabolism of the lipoprotein particle (and its
remnant) under pathophysiological conditions. For example,
apo-E is an important ligand of VLDL-R [36, 39] and can
anchor apo-E-rich lipoproteins to the HSPG site of the
cells [30]. Apo-CII is an activator of LPL, whereas apo-
CIII inhibits the activity of the enzyme [30, 36, 39]. Several
studies have analysed the composition of VLDL particles in
diabetes [70, 71]. Again, however, the results are discrepant.
Increased [72], unchanged [73], and decreased [16, 74] TAG
contents in diabetic VLDL have all been reported. However,
the particle is complex and subtle diﬀerences in lipid or
apoprotein makeup may have a major impact on subsequent
particle eﬃcacy and hence action, and this may in part
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account for the variable findings. Thus, Sambandam et al.
[64] found increased myocardial VLDL metabolism in type
1 diabetes but also reported that there was no apparent
diﬀerence in apolipoprotein composition in VLDL particles
obtained from control and diabetic rats; the authors con-
sidered that VLDL prepared from diabetic rats is a normal
substrate for LPL. This is in contrast to our own findings
[16] (as well as O’Looney’s earlier work [71]) although
both of these studies also demonstrated increased VLDL
metabolism in STZ-induced diabetes. Firstly, we found that
the TAG : PL ratio of VLDL particles from diabetic rats was
significantly lower compared to control VLDL, suggesting
that VLDL particles in type 1 diabetes are smaller (since
TAG : PL ratio approximates to core-to-surface ratio and,
thus, lipoprotein particle size [75]). If this is the case, VLDL
particles would interact less eﬀectively with LPL. Secondly,
apo-E content was increased in diabetic VLDL particles. This
is probably a mechanism for VLDL particles to adapt to
diabetic conditions since increased apo-E content facilitates
the interaction between VLDL and VLDL-R, and hence also
between VLDL and LPL. By contrast, Ishibashi et al. [73]
reported no change in VLDL lipid content but they found
that apo-CIII/CII ratio increased in diabetes, suggesting a
factor contributing to hypertriglyceridaemia since apo-CIII
is an inhibitor of LPL.
Hence, research to date suggests that VLDL is indeed
a key factor in the pathogenesis of hypertriglyceridaemia
and cardiac dysfunction in diabetes, although its precise role
is yet to be fully elucidated. Meanwhile, evidence remains
conflicting; for example, in human type 1 diabetic patients
VLDL metabolism has been reported as normal [72]. Fur-
thermore, Sambandam et al. [64] challenged others’ works
by demonstrating that elevated TAG levels found in STZ-
diabetic rats was abolished after 16-hour fasting, suggesting
that increased chylomicron-TAG may contribute to the
diabetic hypertriglyceridaemia: like VLDL, chylomicrons are
abnormal in composition in diabetes [70, 76] and their
normally rapid peripheral tissue clearance may therefore also
be delayed in this state. Such a mechanism would reconcile
the coexistence of hypertriglyceridaemia (CM) and increased
myocardial TAG-FA metabolism (VLDL) mediated through
LPL and VLDL-R uptake mechanisms.
Interestingly, therefore, changes in myocardial VLDL
utilisation in diabetes can explain the two key features of
this metabolic disorder: hypertriglyceridaemia and diabetic
cardiomyopathy.
5. Is VLDL an Extracardiac Energy Reserve?
By using VLDL particles prepared from perfused livers from
control and diabetic rats, studies to investigate myocardial
VLDL utilisation under normal conditions and in various
metabolic disease states have been conducted in our lab
[16, 18, 66]. From these studies it has emerged that one
possible role of VLDL is to act as an exogenous (extratissue)
energy storage or buﬀer for the heart. Unlike endogenous
myocardial energy storage, that is the intramyocellular pool
of TAG and glycogen, plasma VLDL is farmore quantitatively
significant. Furthermore, since it is delivered by the blood,
it will be accompanied by oxygen, absolutely required for
oxidation of TAG-derived fatty acid. Therefore, the heart
mobilises this pool of TAG to adapt itself to specific
energetic-stress conditions, for example, diabetes and sepsis.
Conversely, the concept of plasma VLDL as a cardiac
TAG buﬀer is supported by the observation of lipoprotein
secreting capacity by the heart [77], permitting two-way
interchange of TAG/lipoprotein between cardiomyocyte and
plasma. Such a mechanism would provide the heart with a
mechanism to prevent lipid overload and hence lipotoxicity.
The key evidence for this is that under physiological
conditions only about half of VLDL-TAG assimilated was
oxidised in the cardiomyocyte [18], and the oxidation rate
of VLDL-TAG was markedly lower than that of CM-TAG
[10, 18] and NEFA [10]. This suggests that the primary
purpose of VLDL delivery to the heart may not be for
oxidation to produce ATP (although the heart did work well
whilst oxidising some of the VLDL-TAG assimilated [10, 18])
under these physiological conditions. By contrast, more than
80% of VLDL-TAG assimilated was oxidised in type 1 [16]
and type 2 [66] diabetes, and the oxidation rate was also
significantly higher than that under physiological workload.
Furthermore, we have demonstrated that cardiac VLDL
metabolism and functional eﬃcacy is significantly increased
in sepsis/endotoxinaemia [17]; VLDL is a better cardiac
substrate in endotoxinaemia, and this is a function of some
change in the composition of the “endotoxic” VLDL particle
rather than the heart itself, since the eﬀect depends on the
endotoxic state of the VLDL and not on the endotoxic state of
the myocardium. This finding was supported by the demon-
stration of altered composition of the VLDL particle secreted
by the endotoxic liver [17, 78, 79]. The primary importance
of the VLDL particle per se in determining its function
and fate is emphasised by the recent observation that
cardiac VLDL-R is downregulated in sepsis/endotoxinaemia
[80]—hence, alterations in VLDL composition are essential
determinants in its utilisation, irrespective of specific uptake
route (indeed “endotoxic” VLDL secreted during sepsis has
been suggested as a vital component of the host immune
response [81, 82]). Again, this argues in favour of a vital
role for VLDL in energy provision in metabolic stress states,
a notion supported by the observation of increased hepatic
VLDL synthesis and secretion in both sepsis [83–86] and
diabetes [70, 87–89]. If VLDL does provide an energy
reserve for the heart, it is understandable that myocardial
VLDL-R expression is increased during the physiological
conditions of development [39] and fasting [43, 47]: the
heart uses this energy storage to adapt itself more eﬃciently
to changing circumstances when undergoing switching of
energy substrates.
These findings indicate that VLDL is mobilised under
specified pathophysiological conditions as a major myocar-
dial energy source to provide ATP for maintenance of cardiac
function.
6. Summary
The role of VLDL, a TAG-rich lipoprotein, in myocardial
energy metabolism has yet to be fully elucidated. Unlike
Journal of Lipids 7
NEFA and CM, VLDL is not a preferred substrate for the
heart under physiological conditions. However, the heart
utilises more VLDL for the production of ATP in diabetes
and sepsis/endotoxinaemia. Also, under other conditions
such as fasting and development, when energy substrate
switching occurs, VLDL appears to be an easily accessed
energy source for the heart. Two possible roles of VLDL in
terms of cardiac energy metabolism have been suggested:
a “metabolic regulator” particularly for LPL activity, and
“exogenous energy storage” for hearts. Further investigations
are required to confirm these roles of the VLDL particle.
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